Articles

Duopharma Biotech Reports Higher 4Q 2021 Revenue Amidst Challenge of Higher Costs

● 4Q revenue grows 8.5% to RM145.44 million compared to previous corresponding quarter
● Second interim dividend of 1.8 sen per share
● New and extended public sector supply contracts, potential tax savings to bolster future earnings

Duopharma Biotech Launches New Flavettes Nutriskincare Range

KUALA LUMPUR, 15 DECEMBER 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) officially launched its new Flavettes Nutriskincare range today, further expanding its consumer healthcare portfolio into the health and beauty segment through the established Flavettes brand. In 2021, Flavettes – the No. 1 Adult Vitamin C brand in Malaysia and a market leader in the effervescent Vitamin C segment, targeted the steadily-growing beauty segment with the introduction of Flavettes Nutriskincare variants – building on the popularity of its effervescent Vitamin C products.

Duopharma Biotech Posts Strong Growth in 3Q 2021

• 3Q PBT rises 21% to RM22.48 million as compared to previous corresponding quarter
• Greater Government emphasis on pharmaceutical sector in mid-term plan and increased budget allocation
for healthcare in Budget 2022 bode well for future earnings

Duopharma Biotech Recognised at Sustainable Business Awards Malaysia 2020/21 

KUALA LUMPUR, 22 OCTOBER 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) was recently recognised as the overall winner at the Sustainable Business Awards Malaysia (SBA) 2020/21 under the Large Organisation category, identifying the company as Malaysia’s leading organisation for sustainability practices. At this year’s event, Duopharma Biotech took home five trophies, in the categories of “Business Ethics & Responsibility”, “Stakeholder Management” and “UN Sustainable Development Goals” as well as receiving the Significant Achievement award in the “Water Management” and “Waste Productivity & Materiality” categories. The awards were presented in the presence of Dato’ Sri Mustapa Mohamed, Minister in the Prime Minister’s Department (Economy). 

Sinopharm Covid 19 Vaccine is Now Available in Malaysia

KUALA LUMPUR, 15 October 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) is further strengthening COVID-19 vaccination efforts in Malaysia with the distribution of the Sinopharm COVID-19 vaccine. Earlier, Duopharma Biotech had entered into an agreement to import the vaccine from Beijing, China, covering a collaboration for the Malaysian market. Duopharma (M) Sdn. Bhd., a wholly owned subsidiary of Duopharma Biotech has been authorised by Sinopharm as the product registration holder and to engage in the sales and distribution of the vaccine.

Duophama Biotech Reports Resilient 2Q 2021 Performance

• 2Q PBT rises 4.2% to RM20.2 million as compared to previous corresponding quarter
• Declares interim dividend of 0.5 sen per share
• Increased Federal Government budget allocation for healthcare sector and extension of public sector supply
agreements to boost future earnings

Duopharma Biotech’s Shareholders Approve Issuance of 235 Million Bonus Shares at Company’s Fully-Virtual Meeting of Members

KUALA LUMPUR, 13 August 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or
“the Company”) held a fully virtual Meeting of Members today, which saw the shareholders
voting to approve the 1-for-3 bonus share issuance which the Company had proposed on 3
May 2021.

Duopharma Biotech Contributes RM1 Million to Malaysia’s Drive to Close Digital Learning Gap

“As exemplified by the CERDIK initiative, closing the digital gap and promulgating digital
learning are among key catalysts required to inclusively build an essential talent platform for
our nation’s growth into the global digital economy,” says Duopharma Biotech Group MD

Duopharma Biotech Granted Conditional Registration Approval for COVID 19 Sinopharm Vaccine

KUALA LUMPUR, 16 July 2021 – Duopharma (M) Sendirian Berhad, a wholly-owned
subsidiary of Duopharma Biotech Berhad (“Duopharma Biotech”), has been granted

conditional registration approval by Malaysia’s Drug Control Authority (“DCA”) for the Covid-
19 Sinopharm vaccine developed by China National Biotec Group Company Limited

(“Sinopharm CNBG”).

Duopharma Biotech Invests USD500,000 in NALURI to Further Empower Malaysia’s Digital Healthcare Vision

Following last year’s SAFE funding round, Duopharma Biotech delivers a further boost via a Series A funding round of Naluri Hidup to enhance homegrown health-tech
‘This is another milestone in Duopharma Biotech’s digital technology journey,’ says Group MD